China CMDE Seeks Comments on Clinical Trial Review Points for Implantable BCI Hand Motor Function Compensation Systems

Core News Content

July 31, 2026. The NMPA Center for Medical Device Evaluation (CMDE) issued a notice seeking public comments on the Technical Review Points for Clinical Trials of Implantable Brain-Computer Interface Hand Motor Function Compensation Systems (Draft for Comments). The feedback deadline is August 19, 2026.

The document is intended to guide applicants in preparing and drafting registration application materials. It will provide technical review references for clinical trial design, evaluation endpoints and safety assessment of implantable BCI hand motor function compensation systems. It may affect the registration pathway, clinical evaluation strategy and technical file preparation for relevant innovative medical devices. It is relevant to BCI device manufacturers and domestic and international manufacturers planning to register such products in the China market.

Source: CMDE Notices. Original publication date: July 31, 2026. Source URL: https://www.cmde.org.cn/xwdt/zxyw/20260731142150145.html. Specific requirements are subject to the latest official release by the regulatory authority.

Full Translated Core Notice

To all relevant units:

To further guide registration applicants in preparing and drafting registration application materials, our Center has organized the preparation of the Technical Review Points for Clinical Trials of Implantable Brain-Computer Interface Hand Motor Function Compensation Systems (Draft for Comments) (Annex 1). Public comments are now invited.

If you have opinions or suggestions, please complete the Comments Feedback Form (Annex 2) and send it by email to our Center before August 19, 2026. Please name the email subject and file in the following format: Comments Feedback on the Technical Review Points for Clinical Trials of Implantable Brain-Computer Interface Hand Motor Function Compensation Systems.

Contacts: Cui Xinyue, Jiang Yan, Wang Zehua

Telephone: 010-86452502, 010-86452514, 010-86452521

Email: jiangyan@cmde.org.cn, wangzh@cmde.org.cn

Annexes:

• Technical Review Points for Clinical Trials of Implantable Brain-Computer Interface Hand Motor Function Compensation Systems (Draft for Comments) (download)
• Comments Feedback Form (download)

National Medical Products Administration, Center for Medical Device Evaluation, July 31, 2026.

AIMEILI Regulatory Interpretation

What this means for medical device companies

This is a regulatory guidance consultation rather than a product-specific approval or safety alert. Companies should assess whether their products, technologies or risk profiles fall within the scope. The draft may influence clinical trial design, endpoints, safety monitoring and the evidence package for registration. It should be translated into concrete compliance actions rather than treated only as industry news.

Regulatory trend and industry impact

CMDE issuing a dedicated consultation for implantable BCI hand motor function compensation systems signals important progress in the oversight of high-end innovative medical devices in China. BCI technology is a frontier interdisciplinary field that previously lacked clear clinical trial technical standards, leaving companies with uncertainty on ethics, subject protection, efficacy evaluation and long-term safety during registration. The draft is expected to provide a unified technical framework for clinical trial design, helping companies clarify trial objectives, primary endpoints and safety monitoring requirements and reducing trial-and-error costs in communications with the review authority.

Impact on registration pathway and product classification

Implantable BCI hand motor function compensation systems typically include implanted electrodes, signal acquisition and processing, and external control units. Product classification and registration pathways may involve active implantable devices, software algorithms and neurostimulation. The consultation indicates that companies should review product technical characteristics against the Medical Device Classification Catalog and relevant classification determination documents as early as possible to clarify the management category and registration pathway. Such products may also qualify for the Special Review Procedure for Innovative Medical Devices. Companies should use early communication channels with CMDE and treat the clinical trial review points as an important reference for application documents.

Clinical evaluation and trial design

Clinical evaluation is one of the core challenges in registering implantable BCI products. The draft is expected to clarify the target population, comparator selection, follow-up duration and primary endpoints, such as improvement in hand motor function, device stability and adverse event rate. Companies need to develop scientifically sound clinical trial protocols, with particular attention to long-term neurological safety of implantation and long-term device reliability. Where overseas clinical trial data are intended to be used, companies should consider ethnic differences and differences in clinical practice, and conduct bridging trials where necessary. This technical review document will directly affect clinical evaluation strategy and warrants prospective planning and sufficient resources.

Technical files, labeling and quality system implications

Even before the final version is issued, companies should monitor several areas. First, product technical requirements should address biocompatibility of implant materials, electrical safety, electromagnetic compatibility and wireless communication stability. Second, labeling and instructions for use should clearly state the indicated population, contraindications, precautions for implantation surgery and long-term follow-up requirements. Third, the quality management system should cover special requirements for implantable devices, including sterility assurance, implant traceability, and collection and reporting of post-operative adverse events. Foreign companies with a China agent should ensure the agent can track regulatory updates, provide comments during consultation and adjust registration strategy accordingly.

Recommended actions

Relevant companies should download and review the full draft as soon as possible and assess the impact on current research and development plans and registration timelines. During the consultation period, companies should consider participating in feedback and seeking clarity on technical issues through CMDE communication channels. For products not yet in the clinical stage, trial protocols should be reviewed against the draft technical framework. For ongoing clinical trials, companies should evaluate whether additional safety endpoints or longer follow-up may be needed.

Business impact

The draft is expected to further standardize the development and review of BCI medical products and support the field's transition from innovation to compliance and maturity. For global manufacturers, early alignment with the draft framework can reduce rework, improve China submission readiness and support evidence generation that meets both local and international expectations. This interpretation is for preliminary planning and does not replace official regulatory requirements.

FAQ

Can the July 31, 2026 draft technical review points be used directly as a basis for regulatory submission?

No. The draft is for preliminary understanding and project assessment. A formal submission must be based on the latest requirements of the target-country regulator, the product classification conclusion and the company's actual documentation.

What should companies do first after seeing this update?

Companies should first conduct a documentation gap assessment. Confirm whether the update affects the registration pathway, technical files, labeling, quality management system or post-market maintenance, and assign owners and timelines for any gaps identified.